ArticleEuropean journal of clinical pharmacology2008
Paediatric clinical pharmacology: at the beginning of a new era.
Article in European journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Systematic review of safety in paediatric drug trials published in 2007.European journal of clinical pharmacology · 2012Pooled it
- Acceptability and Palatability of Novel Orodispersible Minitablets of Enalapril in Children up to the Age of 6 with Heart Failure.Journal of clinical medicine · 2025Article
- Should ACE inhibitors and ARBs be used in combination in children?Pediatric nephrology (Berlin, Germany) · 2019Article
- Dosage form preference consultation study in children and young adults: paving the way for patient-centred and patient-informed dosage form development.European journal of hospital pharmacy : science and practice · 2017Article
- Paediatric clinical pharmacology in the UK.Archives of disease in childhood · 2014Review
- Ethical and legal framework and regulation for off-label use: European perspective.Therapeutics and clinical risk management · 2014Review
- Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches.European journal of pediatrics · 2013Article
- Evaluation of unlicensed and off-label antiepileptic drugs prescribed to children: Brazilian Regulatory Agency versus FDA.International journal of clinical pharmacy · 2013Article
- Reflection: medicines for children--science alone is not enough.European journal of clinical pharmacology · 2013Article
- Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies.European journal of clinical pharmacology · 2013Review
- Children's medicines in Tanzania: a national survey of administration practices and preferences.PloS one · 2013Article
- Ocular medicines in children: the regulatory situation related to clinical research.BMC pediatrics · 2012Review
- The status of paediatric medicines initiatives around the world--What has happened and what has not?European journal of clinical pharmacology · 2012Review
- Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials.European journal of clinical pharmacology · 2011Article
- Framework conditions facilitating paediatric clinical research.Italian journal of pediatrics · 2011Review
- The European paediatric legislation: benefits and perspectives.Italian journal of pediatrics · 2010Article
- The FIMP Medicines for Children Research Network.Italian journal of pediatrics · 2010Article
- Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2010Review
- Drug utilization and off-label drug use among Spanish emergency room paediatric patients.European journal of clinical pharmacology · 2010Article
- Drug prescriptions to outpatient children: a review of the literature.European journal of clinical pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of availability of medicines for children is a large problem. This problem is global. It concerns all children of the world, those in the developing world but also those in the developed world, even in the richest countries. Many generations of paediatricians and other physicians have learned to live with the situation, where more than half of the children are prescribed off-label or unlicensed medicines. However, there is no doubt that medicinal products used to treat the paediatric population should be subjected to ethical research of high quality and be appropriately authorised for use in the paediatric population. Within the last 10 years, the pioneering paediatric initiative in the United States and recent encouraging developments in Europe and at the WHO indicate that change may finally be possible. The developments of the last 2 years have been particularly intensive. It seems that a new era is beginning which will provide unprecedented opportunities but also great challenges for paediatric clinical pharmacologists and other stakeholders working to provide children with the medicines they need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.